Oncohematology

Онкогематология

1818-83462413-4023

Publishing House ABV Press

625

10.17650/1818-8346-2007-0-1-52-56

NOVEL DATA ON WELL-KNOWN DRUGS

НОВОЕ ОБ ИЗВЕСТНЫХ ПРЕПАРАТАХ

The abilities of adequate choice of different asparaginase products

Возможности адекватного выбора различных препаратов аспарагиназы

Popa

A. V.

Попа

А. В.

Russian Federation

НИИ детской онкологии и гематологии РОНЦ им. Н.Н. Блохина, РАМН

22022007

52562211202222112022

2007

https://oncohematology.abvpress.ru/ongm/article/view/625

1. Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea-pig serum: I. Course of transplanted cancer of various kinds in mice and rats given guinea-pig serum , horse serum or rabbit serum. J Exp Med 1953;98:568—82.

Kidd J.G. Regression of transplanted lymphomas induced in vivo by means of normal guinea-pig serum: I. Course of transplanted cancer of various kinds in mice and rats given guinea-pig serum , horse serum or rabbit serum. J Exp Med 1953;98:568—82.

2. Sobin L.H., Kidd J.G. The incorporation of l-asparagin-14C by lymphoma 6C3HED cells: its inhibition by guinea-pig serum. Cancer Res 1966;26(2):208—11.

Sobin L.H., Kidd J.G. The incorporation of l-asparagin-14C by lymphoma 6C3HED cells: its inhibition by guinea-pig serum. Cancer Res 1966;26(2):208—11.

3. Sobin L.H., Kidd J.G. Alterations in protein and nucleic acid metabolism of lymphoma 6C3HED-og cellas in mice given guinea-pig serum. J Exp Med 1966;123(1):55—74.

Sobin L.H., Kidd J.G. Alterations in protein and nucleic acid metabolism of lymphoma 6C3HED-og cellas in mice given guinea-pig serum. J Exp Med 1966;123(1):55—74.

4. Broome J.D. Antilymphoma activity of L-asparaginase in vivo: clearance rate of enzyme preparations from guinea-pig serum and yeast in relation of their effects on tumor growth. J Natl Acad Sci U S A 1965;35:967—74.

Broome J.D. Antilymphoma activity of L-asparaginase in vivo: clearance rate of enzyme preparations from guinea-pig serum and yeast in relation of their effects on tumor growth. J Natl Acad Sci U S A 1965;35:967—74.

5. Yellin T.O., Wriston J.C. Purification and properties of guinea-pig serum asparaginase. Biochemistry 1966;5:1605—12.

Yellin T.O., Wriston J.C. Purification and properties of guinea-pig serum asparaginase. Biochemistry 1966;5:1605—12.

6. Mashburn L.T., Wriston J.C. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964;105:451—2.

Mashburn L.T., Wriston J.C. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964;105:451—2.

7. Asselin B.L., Whitin J.C., Coppola D.J. et al. Compartive pharmacokinetic studies of three aspsraginase preparation. J Clin Oncol 1993;11:1780—6.

Asselin B.L., Whitin J.C., Coppola D.J. et al. Compartive pharmacokinetic studies of three aspsraginase preparation. J Clin Oncol 1993;11:1780—6.

8. Khan A., Hill J.M. Atopic hypersensitivity to L-asparaginase: resistance to immunosuppression. Int Arch Allergy Appl Immunol 1971;40(3):463—569.

Khan A., Hill J.M. Atopic hypersensitivity to L-asparaginase: resistance to immunosuppression. Int Arch Allergy Appl Immunol 1971;40(3):463—569.

9. Ertel I.J., Nesbit M.E., Hammond D. et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphoblastic leukemia: a report from Childrens Cancer Study Group. Cancer Res 1979;39(10):3893—6.

Ertel I.J., Nesbit M.E., Hammond D. et al. Effective dose of L-asparaginase for induction of remission in previously treated children with acute lymphoblastic leukemia: a report from Childrens Cancer Study Group. Cancer Res 1979;39(10):3893—6.

10.

10. Albertsen B.K., Schroder H., Ingerslev J. et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparag-ibase Medac: pharmacokinetics pharmacodynamics, formation of antibodies and influence on coagulation system. Br J Hematol 2001;96(5):983—90.

Albertsen B.K., Schroder H., Ingerslev J. et al. Comparison of intramuscular therapy with Erwinia asparaginase and asparag-ibase Medac: pharmacokinetics pharmacodynamics, formation of antibodies and influence on coagulation system. Br J Hematol 2001;96(5):983—90.

11.

11. Albertsen B.K., Jacibsen P., Schroder H. et al. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemither Pharmacol 2001;48(1):77—82.

Albertsen B.K., Jacibsen P., Schroder H. et al. Pharmacokinetics of Erwinia asparaginase after intravenous and intramuscular administration. Cancer Chemither Pharmacol 2001;48(1):77—82.

12.

12. Albertsen B.K., Schroder H., Jacibsen P. et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmaco 2001;52:433—7.

Albertsen B.K., Schroder H., Jacibsen P. et al. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries. Br J Clin Pharmaco 2001;52:433—7.

13.

13. Sallan S.E., Hitchcock-Bryan S. Gelberg R. et al. Influence of intensive asparaginase in treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43(11):5601—7.

Sallan S.E., Hitchcock-Bryan S. Gelberg R. et al. Influence of intensive asparaginase in treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res 1983;43(11):5601—7.

14.

14. Abshire T.C., Pollock B.H., Billet A.L. et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia leukemia: a Pediatric Oncology Group Study. Blood 2000;96(5):1709—15.

Abshire T.C., Pollock B.H., Billet A.L. et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia leukemia: a Pediatric Oncology Group Study. Blood 2000;96(5):1709—15.

15.

15. Hawkims D.S., Park J.R., Thomson B.G. et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10(16):5335—41.

Hawkims D.S., Park J.R., Thomson B.G. et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10(16):5335—41.

16.

16. Holcenger J.S., Teller D.C. Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A. J Biol Chem 1976;251(17):5375—80.

Holcenger J.S., Teller D.C. Physical properties of antitumor glutaminase-asparaginase from Pseudomonas 7A. J Biol Chem 1976;251(17):5375—80.

17.

17. Avramis V.I., Sencer S., Periclou A.P. et al. Randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Study Group. Blood 2002;99(6):1986—94.

Avramis V.I., Sencer S., Periclou A.P. et al. Randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children’s Cancer Study Group. Blood 2002;99(6):1986—94.

18.

18. Panosyan E.H., Seibel N.L., Gaynon P.S. et al. Asparaginase antibody and asparaginase activity in childhood in higher risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26(4):217—26.

Panosyan E.H., Seibel N.L., Gaynon P.S. et al. Asparaginase antibody and asparaginase activity in childhood in higher risk acute lymphoblastic leukemia: Children’s Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26(4):217—26.

19.

19. Asselin B.L., Whitin J.C., Coppola D.J. et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11(9):1780—6.

Asselin B.L., Whitin J.C., Coppola D.J. et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11(9):1780—6.

20.

20. Boos J., Werber G., Ahlke E. et al. Monitoring of asparaginase activity and asparagine levels in children with different asparaginase preparations. Eur J Cancer 1996;32A(9):544—50.

Boos J., Werber G., Ahlke E. et al. Monitoring of asparaginase activity and asparagine levels in children with different asparaginase preparations. Eur J Cancer 1996;32A(9):544—50.

21.

21. Ahlke E., Nowak-Gottl U., Schultze-Westhoff P. et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia. Br J Hematol 1997;96:675-81.

Ahlke E., Nowak-Gottl U., Schultze-Westhoff P. et al. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukemia. Br J Hematol 1997;96:675-81.

22.

22. Muller H.J., Loning L., Horn A. et al. Pegilated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Hematol 2000;110:379-84.

Muller H.J., Loning L., Horn A. et al. Pegilated asparaginase (OncasparTM) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Hematol 2000;110:379-84.

23.

23. Vieira Pinherio J.P., Ahlke E., Nowak-Gottl U. et al. Pharmacokinetic of dose adjustment of Erwinia asparaginase in protocol II of the pediatric ALL/NHL-BFM treatment protocols. Br J Hematol 1999;104:313-20.

Vieira Pinherio J.P., Ahlke E., Nowak-Gottl U. et al. Pharmacokinetic of dose adjustment of Erwinia asparaginase in protocol II of the pediatric ALL/NHL-BFM treatment protocols. Br J Hematol 1999;104:313-20.

24.

24. Vieira Pinherio J.P., Muller H.J., Schwabe D. et al. Drug monitoring of low dose PEG-asparaginase (Oncaspar™) in children with relapsed acute lymphoblastic leukemia (ALL). Br J Hematol 2001;113:115-9.

Vieira Pinherio J.P., Muller H.J., Schwabe D. et al. Drug monitoring of low dose PEG-asparaginase (Oncaspar™) in children with relapsed acute lymphoblastic leukemia (ALL). Br J Hematol 2001;113:115-9.

25.

25. Muller H.J., Beier R., da Palma J.C. et al. PI^G-asparaginase (Oncaspar™) 2,500 U/m BSA in re-induction and relapse treatment of the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002;49:149-54.

Muller H.J., Beier R., da Palma J.C. et al. PI^G-asparaginase (Oncaspar™) 2,500 U/m BSA in re-induction and relapse treatment of the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002;49:149-54.

26.

26. Gaynon P.S., Harris R.E., Stram S.O. et al. Asparagine (ASN) depletion and treatment response in chikdhood acute lymphoblastic leukemia (ALL) after an early marrow relapse: a Children’s Cancer Group trial (CCG-1941) [abstract]. Blood 1999;94(10 Suppl 1):628a.

Gaynon P.S., Harris R.E., Stram S.O. et al. Asparagine (ASN) depletion and treatment response in chikdhood acute lymphoblastic leukemia (ALL) after an early marrow relapse: a Children’s Cancer Group trial (CCG-1941) [abstract]. Blood 1999;94(10 Suppl 1):628a.

27.

27. Panosyan E., Avramis I.A., Seibel N.L. et al. Glutamine (Gln) deamonation by asparaginases (ASNases) in children with high risk acute lymphoblastic leukemia (HR ALL), (CCG-1961 study) [abstract]. Blood 2002;100:759A.

Panosyan E., Avramis I.A., Seibel N.L. et al. Glutamine (Gln) deamonation by asparaginases (ASNases) in children with high risk acute lymphoblastic leukemia (HR ALL), (CCG-1961 study) [abstract]. Blood 2002;100:759A.

28.

28. Avramis V.I., Panosyan E.H. Pharmacokinetic/Pharmacodynamic relations of asparaginase formulations the past, the present and recommendations for the future. Clin Pharmacokokinet 2005;44(4):367-93.

Avramis V.I., Panosyan E.H. Pharmacokinetic/Pharmacodynamic relations of asparaginase formulations the past, the present and recommendations for the future. Clin Pharmacokokinet 2005;44(4):367-93.

29.

29. Vieira Pinherio J.P., Wenner K., Escherich G. et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 U/m PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006;46:18-25.

Vieira Pinherio J.P., Wenner K., Escherich G. et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 U/m PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006;46:18-25.

30.

30. Rizzari C., Zucchetti M., Conter V. et al. L-Asparagine depletion and L-asparag-inase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C or E. coli L-asparaginase as the first exposure. Ann Oncol 2000;11(2):189-93.

Rizzari C., Zucchetti M., Conter V. et al. L-Asparagine depletion and L-asparag-inase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C or E. coli L-asparaginase as the first exposure. Ann Oncol 2000;11(2):189-93.

31.

31. Avramis V.I., Senser S., Periclou A.P. et al. A randomized comparison of native Escherichia coli aspsraginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002;99:1986-94.

Avramis V.I., Senser S., Periclou A.P. et al. A randomized comparison of native Escherichia coli aspsraginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard risk acute lymphoblastic leukemia: a Children’s Cancer Group study. Blood 2002;99:1986-94.

32.

32. Appel I.M., Pinheiro JPV., den Boer M.K. et al. Lack of asparagines depletion in the ceredrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 2003;17:2254-6.

Appel I.M., Pinheiro JPV., den Boer M.K. et al. Lack of asparagines depletion in the ceredrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Leukemia 2003;17:2254-6.